Abstract:Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and among the leading causes of cancer-related deaths worldwide.[1] [2] While early-stage HCC is amenable to curative therapy, intermediate- and late-stages require a team of hepatologists, surgeons, oncologists, and interventional radiologists to optimize treatment. Several staging systems have been proposed in the management of HCC, the most prominent being the Barcelona Clinic Liver Cancer (BCLC) Staging System which is endorsed by leading organizations in Europe and North America.[3] According to the BCLC System, HCC stage is assessed using measures of tumor burden, performance status, and liver function. Tumor burden incorporates the size, location, and number of lesions as well as portal invasion or extrahepatic spread. Performance status is determined using the Eastern Cooperative Oncology Group (ECOG) criteria.[4] Finally, liver function is classified as "preserved" or "end-stage." Measures of liver function have traditionally relied on Child–Pugh (CP) scores which stratify patients into three classes of liver function based on serum bilirubin, albumin, coagulation, and the presence or absence of ascites and hepatic encephalopathy.[5] The Model for End-Stage Liver Disease (MELD) scoring system, originally developed to predict outcomes of patients undergoing transjugular intrahepatic portosystemic shunt, overcomes some limitations of the CP system, namely, the subjectivity in rating ascites or encephalopathy which could inappropriately be used to benefit a patient's position on transplant lists.[6] New BCLC recommendations suggest incorporating α fetoprotein and albumin–bilirubin scores to accurately assess liver function in addition to these traditional measures. Tumor burden, performance status, and liver function are used in conjunction to stratify HCC into very early stage (0), early stage (A), intermediate stage (B), advanced stage (C), and terminal stage (D) ([Table 1]). Tumor burden Performance status Liver function Very early stage (0) Single ≤ 2 cm 0 Preserved Early stage (A) Single, or ≤ 3 nodules each ≤ 3 cm 0 Preserved Intermediate stage (B) Multinodular 0 Preserved Transplant-eligible Meets extended liver transplant criteria (size, AFP levels) TACE-eligible Well-defined nodules, preserved portal flow, selective access 0 Preserved Recommended for systemic therapy Diffuse, infiltrative, extensive bilobar liver involvement Advanced stage (C) Portal invasions, extrahepatic spread 1–2 Preserved Terminal stage (D) Any tumor burden 3–4 End-stage liver function Abbreviations: AFP, α fetoprotein; TACE, transarterial chemoembolization. The most recent BCLC Staging System was published in 2022 and contains several changes from the 2018 iteration. For one, the 2022 version stratifies intermediate stage (B) HCC into three categories: transplant eligible, TACE eligible, or recommended for systemic therapy.[7] This is a change from the 2018 guidelines which recommended chemoembolization for all intermediate stage (B) lesions, drawing criticism of suboptimal recommendations for such a heterogeneous grouping of patients.[3] This stratification is considerably important for interventional radiologists to be aware of as management of stage B HCC now depends on the nature and/or extent of tumor involvement as well as patients' transplant eligibility. Furthermore, TACE and transarterial radioembolization (TARE) are now recommended as second-line treatments when transplant, ablation, or resection fails in Stage 0 or A HCC.[7] Notably, the recommendations for TARE are limited to lesions ≤ 8 cm based on results of the LEGACY study.[8] In general, it is worth noting that liver transplantation has become increasingly more prevalent in the long-term management of HCC compared with prior BCLC iterations. This is because of the high risk of recurrence of HCC of up to 70% within 5 years after ablation or surgical resection.[9] Liver transplantation is theoretically curative for both HCC and underlying liver disease, and demonstrates ∼50 to 70% survival within 5 years; however, a 10 to 20% reported incidence of HCC recurrence still exists in this patient population.[10] [11] TACE and TARE can be used as bridging treatments prior to transplant, and have demonstrated effectiveness in halting tumor progression and reducing waitlist dropout rates for patients with liver cirrhosis and HCC.[12] [13] [14] [15] Given the increasing prevalence of transplantation as a definitive treatment for HCC and the demonstration of TACE and TARE as effective strategies for improving access to transplantation, this approach to downstaging and bridging to transplant has been included in the 2022 iteration of the BCLC guidelines. New modifications to the role of IR interventions in HCC are summarized in [Table 2]. BCLC 2018 iteration BCLC 2022 iteration Tumor ablation BCLC -Abstract Truncated-

Towards Context-Based Concurrent Formal Theories

Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms

Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.

Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents

Survival impact of pre-transplant local treatments in liver transplant recipients with BCLC stage A hepatocellular carcinoma

Beta-lactoglobulin structure and retinol binding changes in presence of anionic and neutral detergents.

Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias

Comparison of Long-Term Survival of Patients with Bclc Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization

The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable

Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.

Ideal patients for liver resection in Barcelona Clinic Liver Cancer or Hong Kong Liver clinic systems for hepatocellular carcinoma: Conservative or aggressive?

Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma

Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice

PTH-110 Long term survival following treatment for hepatocellular carcinoma in patients with hereditary haemochromatosis

Preferred Treatment with Curative Intent for Left Lateral Segment Early Hepatocellular Carcinoma under the Era of Minimal Invasive Surgery

Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System

Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort Study

Hyperpolarization-activated inward chloride current in protoplasts from suspension-cultured carrot cells

Why Cannot BCLC 0- or A-Stage Patients Receive Curative Treatment?